Brought to you by 
Elitra, Merck & Co. develop antibiotics
07 Nov 2001
Executive Summary
Merck & Co will screen Elitra Pharmaceuticals' (antimicrobial functional genomics) targets against its natural product and compound libraries to discover and then develop antibiotic drugs. Merck gets exclusive worldwide rights to resulting products.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Molecular Diversity
- Natural Products
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elitra, Merck & Co. develop antibiotics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice